Quantcast

Latest NS5 Stories

2011-11-07 23:30:00

⢠Results add to data suggesting that SVR can be achieved with the combination of daclatasvir (BMS-790052) and asunaprevir (BMS-650032) in HCV genotype 1b patients ⢠Study expanded to include alfa/RBV ineligible or intolerant patients Princeton, NJ (PRWEB) November 07, 2011 Bristol-Myers Squibb Company (NYSE: BMY) today announced results from a ten patient sentinel cohort of an ongoing Phase II study in which treatment with a dual, all-oral...

2011-07-06 05:45:00

PRINCETON, N.J., July 6, 2011 /PRNewswire/ -- Pharmasset, Inc. (NASDAQ: VRUS), announced today that it has entered into a clinical collaboration agreement with Tibotec Pharmaceuticals to evaluate in a Phase 2 study the safety and efficacy of PSI-7977, Pharmasset's investigational nucleotide polymerase inhibitor, in combination with TMC435, Tibotec Pharmaceuticals' investigational protease inhibitor, for the treatment of chronic hepatitis C virus (HCV). This phase 2 proof of concept study...

2011-06-22 05:45:00

PRINCETON, N.J., June 22, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces that the United States Patent and Trademark Office has issued U.S. patent 7,964,580 ("the '580 patent") titled "Nucleoside Phosphoramidate Prodrugs". This patent generally relates to the composition of matter of PSI-7977 and its diastereomeric mixture for the treatment of hepatitis C virus (HCV). PSI-7977, a uracil nucleotide analogue polymerase inhibitor of HCV, is being studied in multiple phase 2...

2011-05-26 05:45:00

PRINCETON, N.J., May 26, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today the initiation of a Phase 2a trial investigating the combination of Pharmasset's PSI-7977, a nucleotide polymerase inhibitor, and BMS-790052, Bristol-Myers Squibb Company's (NYSE: BMY) NS5A replication complex inhibitor, for the treatment of chronic hepatitis C (HCV). This trial is the result of a clinical collaboration agreement between Pharmasset and Bristol-Myers Squibb announced in January...

2011-05-18 11:30:00

ABBOTT PARK, Ill., May 18, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it has received approval from the U.S. Food and Drug Administration to market its RealTime PCR (polymerase chain reaction) test for measuring the viral load of hepatitis C (HCV), the leading cause of liver cancer in the United States. The Abbott RealTime HCV assay, developed for use on the Abbott m2000 system, is intended for use as an aid in the management of HCV-infected patients undergoing...

2011-05-04 15:00:00

BRISBANE, Calif., May 4, 2011 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that Dan Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the Bank of America Merrill Lynch 2011 Health Care Conference in Las Vegas, NV on May 11, 2011, at 1:00 p.m. PDT. To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at www.intermune.com....

2011-04-03 22:03:31

Is this treatment approach the next HCV therapy frontier? Exciting new data presented today at the International Liver CongressTM 2011 show that quadruple therapy in chronic hepatitis C (HCV) patients suppressed the emergence of resistant variants and resulted in a 100% rate of sustained virological response - undetectable HCV RNA - 12 weeks after treatment (SVR12). In the quadruple therapy study, HCV patients were given four drugs in combination; pegylated Interferon-alpha (PegIFN-alpha);...

2011-04-03 21:53:40

Rapid resistance to novel anti-viral therapy develops in response to direct antiviral drugs Data presented at the International Liver CongressTM highlight the fact that new novel antiviral compounds for the treatment of hepatitis C virus (HCV) must be prescribed and monitored by experts and specialists to ensure resistance is minimized. Several studies observed the rapid onset of HCV resistance in patients treated with NS3-protease, NS5b-polymerase and NS5a inhibitors. Although these direct...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related